

26–27 NOVEMBER 2026
MALLORCA, SPAIN

NAVIGATING TREATMENT DECISIONS IN PROSTATE CANCER: CURRENT STRATEGIES & FUTURE DIRECTIONS

Hotel Victoria Gran Meliá,
Avenida Joan Miró 21, 07014 Palma

SCIENTIFIC RATIONALE

Prostate cancer care is entering an era of increasingly individualized treatment. From risk-adapted screening and advances in diagnostic imaging to evolving concepts in focal therapy, systemic treatment intensification, and precision oncology, clinicians are faced with a growing number of therapeutic options across both localized and advanced disease settings. Navigating these choices requires a critical appraisal of emerging evidence, careful patient selection, and multidisciplinary collaboration. The meeting "**Navigating Treatment Decisions in Prostate Cancer: Current Strategies & Future Directions**" brings together leading experts to discuss current challenges, ongoing controversies, and future developments in prostate cancer management. By combining state-of-the-art lectures, interactive debates, and real-world case discussions, the program aims to support evidence-based decision-making and optimize patient care across the entire prostate cancer continuum.

FACULTY

SCIENTIFIC DIRECTOR

Markus Graefen

Medical Director, Martini-Klinik am UKE; **Professor** of Urology, University Medical Center Hamburg-Eppendorf, Germany

Sigrid V. Carlsson

Division Head, Epidemiologist, Division of Clinical Epidemiology of Early Cancer Detection, German Cancer Research Center, Heidelberg, Germany

Caroline M. Moore

Professor of Urology & Head of Urology, University College London; **Honorary Consultant** Urological Surgeon, UCLH, United Kingdom

Paweł Rajwa

Professor of Urology, Department of Urology, Medical University of Silesia, Katowice, Poland; Medical University of Vienna, Austria

Daniel Eberli

Professor for Urology, University of Zürich, Switzerland

Gunhild von Amsberg

Professor of Uro-Oncology, University Cancer Center Hamburg & Martini-Klinik, University Medical Center, Hamburg-Eppendorf, Germany

Alberto Bossi

Clinical Head, Department of Radiotherapy, Charlebourg-La Défense, Groupe Amethyst, La Garenne-Colombes, France

THURSDAY, 26 NOVEMBER 2026
LOCALIZED PROSTATE CANCER

14:00	**Welcome, Opening Remarks and Introduction of the Faculty** Markus Graefen
14:05-15:15	**SCREENING AND EARLY DETECTION** Moderators: Paweł Rajwa and Markus Graefen
14:05	**Smart Screening in Europe in 2026** Sigrid Carlsson Q&A and voting
14:40	**From MRI to Biopsy: Optimising the Diagnostic Pathway** Caroline Moore Q&A and voting
15:15-16:30	**ACTIVE SURVEILLANCE AND FOCAL THERAPY** Moderators: Caroline Moore and Sigrid Carlsson
15:15	**Active Surveillance in 2026: Selecting, Monitoring and Knowing When to Act** Paweł Rajwa Q&A and voting
15:50	**Focal Therapy: Bridging Guidelines and Real-World Practice** Daniel Eberli Q&A and voting

THURSDAY, 26 NOVEMBER 2026
LOCALIZED PROSTATE CANCER

16:30 *Break - 30 min*

17:00 **Debate: Optimal Treatment for Localized Prostate Cancer**
Moderators: Gunhild von Amsberg and Daniel Eberli

Arguments for radical prostatectomy · Markus Graefen
Arguments for radiotherapy · Alberto Bossi

17:30 **Tumour Board - Cases and Live Voting**
Moderators: Alberto Bossi and Paweł Rajwa

Active Surveillance · Focal · Radiotherapy · Surgery

Case 1 · Daniel Eberli
Case 2 · Caroline Moore

Interactive Case Voting and Panel Discussion

18:00 **Closing Remarks**
Markus Graefen

19:30 *Dinner*

FRIDAY, 27 NOVEMBER 2026
ADVANCED PROSTATE CANCER

09:00 **Locally Advanced Disease: Role of localized treatments**

Moderators: Caroline Moore and Paweł Rajwa

The case for radiotherapy + hormones · Alberto Bossi
The case for surgery · Markus Graefen

09:30 **The Hormonal Backbone: Optimising ADT and ARPI Combinations**

Gunhild von Amsberg

Q&A and voting

10:00 **When First-Line Fails: A Roadmap to Salvage Therapy**

After HIFU · Caroline Moore
After radiotherapy · Paweł Rajwa
After surgery · Markus Graefen

10:30 **Oligometastatic Prostate Cancer - Treatment Options**

Daniel Eberli

Surgery · ARPI · radiotherapy · metastasis directed therapy

11:00 *Break - 30 min*

FRIDAY, 27 NOVEMBER 2026
ADVANCED PROSTATE CANCER

11:30 **Tailoring Treatment Intensity in mHSPC: Balancing Efficacy, Toxicity, and Patient Selection**
Gunhild von Amsberg

Q&A and voting

12:05 **On the Horizon: The Emerging Prostate Cancer Pipeline**
Gunhild von Amsberg

12:25 **Tumour Board - Advanced & Metastatic Prostate Cancer**
Moderators: Caroline Moore and Paweł Rajwa

Cases and live voting: locally advanced · oligometastatic · mHSPC (doublet vs triplet) · mCRPC sequencing · PSMA theranostics

Case 1 · Gunhild von Amsberg
Case 2 · Daniel Eberli

12:50 **Closing Remarks**
Markus Graefen

13:00 *Lunch*



PROVIDER CME AND SECRETARIAT

EUREKA

SUPPORTED BY AN UNRESTRICTED EDUCATIONAL GRANT FROM

RECORDATI

UEMS-EACCME ACCREDITATION

LEE/2026/01967

The **Navigating treatment decisions in prostate cancer: current strategies & future directions, Majorca, Spain 26/11/2026 - 27/11/2026**, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **6.0 European CME credits** (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at https://edhub.ama-assn.org/pages/applications.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

EACCME® credits

Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation at the event once he/she has completed the feedback form. Cf. criteria 22 of UEMS 2023.07.

In order to help you issue individual certificates to each participant, please find below the breakdown of ECMEC®s per day:

26/11/2026 - 3.0

27/11/2026 - 3.0

The EACCME® awards ECMEC®s on the basis of 0,5 ECMEC® for 30 minutes of CME with a maximum of 8 ECMEC®s per day. cf. Chapter XIII of UEMS 2023.07.